Kornimate/medical-research-clean huggingface dataset:
effects of kangaroo mother care among low birth weight (lbw) and preterm infants

Conditions: LBW; Preterm

Summary: - hypothermia, infections ,and ineffective breastfeeding are some of the commonest causes of deaths among premature and low birth weight lbw infants. even if the infants are born in facilities, incidences of cold stress are possible due to insufficient resources, space and incompetent practices to manage hypothermia in the immediate postnatal period. kangaroo mother care is a well-known intervention to address the issues related to preterm births, such as hypothermia, infection and prolong hospitalization.besides significant outcome of kmc interventions for preterm infants, no interventional study has been found in literature in pakistani context. looking at the potential benefits of kmc in reducing the related complications of prematurity, the study aims to identify the effectiveness of kmc among preterm and lbw infants born in secondary hospital of aga khan university hospitals. hypothesis i ha: kmc is effective in reducing the incidences of hypothermia among preterm and lbw infants as compared to the usual care. hypothesis ii ha: there is a difference in breastfeeding behavior and breastfeeding outcome among experimental and control group. secondary hypothesis hypothesis i ha: there is an association between kmc and frequency of suspected infections during hospitalization. hypothesis ii ha: there is a difference in length of stay among experimental group and control group. hypothesis iii ha: there is a relationship between kmc and weight gain of infants till four weeks. hypothesis iv ha: there is difference in rate of hypothermia among experimental group and control after discharge from hospital.


Eligibility criteria:
inclusion criteria: * any preterm neonates (\< 37 weeks of gestation by maternal dates) * low birth weight infants less than 2500 gm. exclusion criteria: * infants with brain hemorrhage, congenital abnormalities. * infants needed double phototherapy. exclusion of mother: mothers with severe depression, sickness with intensive care requirements. mother who refused to participate. mothers who delivered live multiple babies.

Keywords: effects kmc lbw preterm temperature breastfeeding secondary hospitals
eltgol and bronchiectasis. respiratory therapy

Conditions: Respiratory; Complications, Therapy; Bronchiectasis

Summary: the eltgol technique improves mucociliary clearance in adult patients with bronchiectasis. primary objective: -to evaluate the efficacy of eltgol in stable state patients with bronchiectasis compared to placebo. secondary objectives: * to evaluate the level of knowledge of airway clearance techniques and adherence to them in patients with bronchiectasis. * to assess the side effects during the procedure: oxygen desaturation, increased dyspnea and hemoptysis.

the incidence of bronchiectasis has increased in recent years resulting in greater costs, including periods of hospitalisation and the prescription of drugs. the mucociliary clearance mechanism is impaired in these patients, and chest physiotherapy has been recommended for patients with bronchiectasis and chronic productive cough and/or evidence of mucus plugging on hrct. however, to date, there is insufficient evidence of benefits of chest physiotherapy through randomised controlled trials. furthermore it rests unclear the most effective technique, the frequency and optimum duration of the rp and the most suitable variables to monitor. a multicenter clinical trial into the efficacy of one chest physiotherapy technique in airway clearance will fill this important "gap" in the scientific evidence.

Eligibility criteria:
inclusion criteria: * all subjects ≥ 18 years old. * diagnosis of bronchiectasis using a high-resolution computed tomography (hrct) chest scan performed in the last 2 years. * clinically stable disease (defined as no requirement for antibiotics for exacerbation in the 4 weeks preceding study entry. * chronic sputum expectoration \>10ml/24h. exclusion criteria: * bronchiectasis secondary to cystic fibrosis. * inability to perform physiotherapy techniques. * inability to attend the following controls. * treatment with mucolytics, dnase or hypertonic saline during the study. * smokers and ex-smokers ≥ 10 pack/year.

Keywords: bronchiectasis respiratory therapy airway clearance
effects of abdominal nerve block on postoperative recovery in patients undergoing gastrointestinal surgery

Conditions: Colon Cancer; Rectal Cancer; Gastric Cancer

Summary: to explore the effect of general anesthesia combined with transversus abdominis plane block (tapb) and/or rectus sheath block (rsb) on the recovery of patients with gastrointestinal tumor after surgical treatment.


Eligibility criteria:
inclusion criteria: 1. aged 18 to 80 years. 2. asa 1-3. 3. clinical diagnosis of gastric carcinoma and colorectal cancer without metastasis. 4. surgery for gastrointestinal surgery. exclusion criteria: 1. patients and their family members refuse to accept the clinical trial; 2. complicated with acute cholangitis, gastrointestinal bleeding or ascites, etc.; 3. hepatic encephalopathy, psychosis or neuropathy; 4. body weight for acid-base and electrolyte imbalances, endotoxemia, and cachexia decreased by more than 2% or 5% in the past 2 months or 6 months. 5. uncontrolled hypertentsion, coronary heart disease, diabetes.
the comparison between hepasphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma

Conditions: Advanced Hepatocellular Carcinoma (HCC)

Summary: transarterial chemoembolization (tace) is widely applied and shows good efficacy in advanced hepatocellular carcinoma (hcc). recently, hepatic arterial infusion chemotherapy (haic) has also gained popularity in the treatment of hcc. several studies have described the comparison between haic and tace or tace combined with haic. however, the evaluation between tace plus haic and haic is rarely reported. here, we will evaluate the performance of hepasphere deb-tace combined with haic (hepa-haic) comparing to haic in patients with advanced hcc

this is a double-arm, retrospective, observational study. the patients diagnosed as advanced hcc and treated with hepasphere plus haic or single haic in the interventional therapy department of peking university cancer hospital \& institute from may 2018 to may 2022. these patients are grouped into two cohorts. one is hepa-haic group, the other is haic group. to access the effect of hepasphere plus haic and single haic on the treatment of advanced hcc, the treatment efficacy and safety will be analyzed between these two cohorts. to avoid the selection bias, propensity score matching (psm) will be also conducted. the primary endpoints are progression-free survival (pfs) and overall survival (os); the secondary endpoint includes objective response rate (orr), disease control rate (dcr) and safety

Eligibility criteria:
inclusion criteria: * age: ≥18 years old * gender: no limitation * diagnosed as primary hepatocellular carcinoma histologically or clinically * imaging data within 31 days at enrollment and at least one measurable lesion (according to mrecist criteria) is available * patients only received treatment with hepasphere combined with hepatocellular arterial infusion chemotherapy (haic) or haic alone during the observation period * child-pugh: a-b * ecog: 0-2. exclusion criteria: * other cancer diseases are co-existed * drug-eluting beads from other manufacturers were used during deb-tace * deb-tace combined with haic or haic alone was used as postoperative adjuvant therapy * pre- or post-surgery relevant examination results were unavailable * imaging information for effectiveness evaluation was unavailable * follow-up failure due to patient information errors, loss, refusal, etc

Keywords: hepasphere transarterial chemoembolization tace hepatic arterial infusion chemotherapy haic
a drug-drug interaction study to evaluate the effect of ripretinib on the pharmacokinetics of a cyp2c8 probe substrate in patients with advanced gist

Conditions: GIST - Gastrointestinal Stromal Tumor

Summary: evaluate the effect of ripretinib on the pharmacokinetics of a cyp2c8 substrate


Eligibility criteria:
inclusion criteria: 1. patients ≥18 years of age. 2. patients must have a histologic diagnosis of gist. 3. patients must have gist that has progressed on or have intolerance to at least 2 lines of prior tki therapies. 4. patients must have an eastern cooperative oncology group performance score of ≤ 2. 5. if a female of childbearing potential, must have a negative pregnancy test prior to enrollment and agree to follow the contraception requirements. 6. adequate organ and bone marrow function. exclusion criteria: 1. received prior anticancer or other investigational therapy within 28 days or 5× the half-life prior to the first dose. 2. prior treatment with ripretinib. 3. patients who have had prior repaglinide treatment within 14 days prior to cycle 1 day 1. 4. history or presence of clinically relevant cardiovascular abnormalities. 5. gastrointestinal abnormalities including but not limited to: * inability to take oral medication, * malabsorption syndromes, * requirement for intravenous alimentation. 6. patients who have type 1 or type 2 diabetes.
a study in participants with psoriatic arthritis attending dermatology clinics

Conditions: Psoriatic Arthritis

Summary: the purpose of this study is to conduct full psychometric testing of the early arthritis for psoriatic patients (earp) questionnaire in australian, korean and chinese populations

this is a multicentre, observational, descriptive estimate of the proportion of participants with psoriatic arthritis among psoriasis participants attending dermatology clinics selected for this study. in addition, this study will involve full psychometric assessment of the early psoriatic screening questionnaire (earp) questionnaire with the aim of identifying and appropriately referring participants to a rheumatologist for review if their earp score is 3 or greater at screening (i.e. \>= 3 at visit 1).

Eligibility criteria:
inclusion criteria: * patient must be a man or woman aged 18 to 65 years of age, inclusive * the patient must have an established diagnosis of psoriasis (based upon clinical evidence, and documented medical history \[19\]) * the patient must be able to read and write in the target language (english, mandarin or korean; or other relevant target languages) * each patient must sign an informed consent form (icf) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study exclusion criteria: * an established diagnosis of psoriatic arthritis * ever have received systemic treatment with a disease modifying antirheumatic drug (dmard) for arthritis or spondylitis (inflammatory back pain) * ever have received systemic treatment with a biologic therapy for psoriasis (including infliximab, golimumab, ustekinumab, adalimumab or etanercept) * a history of employment in or are currently employed in the healthcare industry; or * participated in the translation and linguistic validation of the earp questionnaire

Keywords: psoriatic arthritis
use of positive pressure in morbidly obese patients undergoing reduction stomach surgery

Conditions: Pulmonary Atelectasis; Respiratory Tract Diseases; Pathological Conditions, Signs and Symptoms

Summary: the aim of this study was to investigate the effects of using positive pressure in the preoperative, intraoperative and postoperative morbidly obese individuals undergoing gastroplasty. it is believed that the application of these devices before, during or after surgery can help to improve the lungs and reduce pulmonary complications after surgery to reduce the stomach.

the aim of this study was to investigate the effects of using positive pressure in the preoperative, intraoperative and postoperative morbidly obese individuals undergoing roux-en-y gastric bypass with regard to: lung volumes and capacities, the prevalence of atelectasis, duration of surgery and diaphragmatic mobility. individuals with bmi between 40 and 55 kg/m2, aged between 25 and 55 years, were submitted to roux-en-y type gastric bypass by laparotomy. patients showing a normal preoperative pulmonary function test were included, but those with hemodynamic instability, a hospital stay longer than three days or the presence of postoperative complications were excluded. the volunteers were divided into four different groups: gpre: subjects treated with positive pressure in the bipap mode (bi-level positive airway pressure) for one hour before surgery; gpos: individuals treated with positive airway pressure (bipap) for one hour after surgery; gpeep: individuals treated with 10 cm h2o of peep (positive end expiratory pressure) during the surgical procedure. gcont: individuals treated with conventional physiotherapy (cp) according to the routine service of physiotherapy of the hospital, including the techniques of pulmonary re-expansion, breathing exercises (deep breaths or fractional), the use of incentive spirometry (respiron®), bronchial hygiene resources if necessary (flutter® and cough active or assisted) and assisted ambulation. it should be noted that the physiotherapist was blinded to the individual's participation in the groups, and all patients received conventional physiotherapy, independent of the group in which they were included. the respiratory evaluation (preoperative and second postoperative days) consisted of collecting the anthropometric data, a pulmonary function test and a chest radiography (inspired and expired).

Eligibility criteria:
inclusion criteria: * bmi between 40 and 55 kg/m2 * aged between 25 and 55 years * submitted to roux-en-y type gastric bypass by laparotomy * normal preoperative pulmonary function test exclusion criteria: * hemodynamic instability * hospital stay longer than three days * presence of postoperative complications

Keywords: morbid obesity bariatric surgery pulmonary atelectasis spirometry continuous positive airway pressure physical therapy specialty
comparison of remifentanil and dexmedetomidine for monitored anaesthesia care during vertebroplasty and kyphoplasty

Conditions: Fractures, Compression

Summary: this randomised, double-blind study compared remifentanil and dexmedetomidine for monitored anaesthesia care (mac) during minimally invasive corrections of vertebral compression fracture (vertebroplasty (vp) and kyphoplasty (kp)). in total, 80 asa physical status i-iii patients scheduled for vp and kp randomly received remifentanil or dexmedetomidine to maintain oaa/s scale ≤ 4 during the procedures. multiple hemodynamic variables of patients were recorded and the frequency of oxygen desaturation, respiratory depression, intraoperative need for other opioids, recovery time, operator satisfaction score, and patients' overall pain experiences were also compared. the investigators are expecting that both remifentanil and dexmedetomidine appear to be quite safe for mac during vp and kp. thus, dexmedetomidine may be an alternative for mac during vp and kp in elderly patients.

all patients fasted for 8 h before the procedure and were premedicated with midazolam 0.02 mg/kg. in the prone position, patients were monitored by ecg, non-invasive blood pressure, and pulse oximetry, and received supplemental oxygen (3 l/min) via a nasal cannula during the procedure. study drugs were prepared in 20 ml and 50 ml syringes to maintain a double-blind design. one anaesthesiologist administered normal saline or dexmedetomidine contained in the 20-ml syringe during the initial 10 min for loading dose of dexmedetomidine. then, another investigator who did not know which syringes contained remifentanil or dexmedetomidine adjusted the infusion rate with a 50-ml syringe according to patients' response. after all patients in both groups received a bolus dose of propofol 0.3 mg/kg, patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h, and patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of dexmedetomidine 0.2-1 µg/kg/h throughout the procedure. levels of patient sedation were checked during the procedure and infusion rates of the study drugs were adjusted to maintain alertness/sedation below 4 on the oaa/s scale. mean arterial pressure (map), heart rate (hr), oxygen saturation (spo2), respiratory rate (rr), and adverse effects of the study drugs were recorded during the procedure. ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmhg. duration of pacu stay was also recorded. operator satisfaction score and patient's overall pain experience were also recorded.

Eligibility criteria:
inclusion criteria: * patients who are scheduled for vertebroplasty or kyphoplasty under monitored anesthesia care * asa status i-iii * aged more than 65 years old. exclusion criteria: * obesity (bmi \> 30 kg/m2) * hypotension (systolic blood pressure \< 100 mmhg) * bradycardia (heart rate \< 60 bpm) * heart block * baseline oxygen desaturation (spo2 \< 90%) * sleep apnea * asthma, or chronic obstructive pulmonary disease * those who refused to give informed consent
unilateral peripheral vestibular dysfunction: reeducation and spatial orientation.

Conditions: Inner Ear Disease; Equilibrium; Disorder, Labyrinth; Spatial Navigation

Summary: motor control includes postural control and voluntary movement. for an optimal motor control it is necessary that brain integrates vestibular, visual and somatosensorial inputs properly, in a nonlinear way. vestibular system, as an afferent organ, encodes head position in relation to gravity and changes in its linear and angular acceleration. as vestibular central system, it plays an essential role in motor control and in orientation and spatial memory as well. when a peripheral vestibular lesion occurs, elaboration, interpretation and processing of inputs are deficient and therefore motor control is altered to a greater or lesser degree. as process progress in time, there is a natural neuroplasticity that facilitates recovery or compensate vestibular function, although sometimes this process is incomplete and requires vestibular reeducation this study aims to assess changes in balance control, orientation and handicap perception in one case group with symptomatic unilateral peripheral vestibular dysfunction, before and after a rehabilitation programme (rv). to compare values obtained at the beginning and at the end of rv to those achieved by control group. finally, this research aims to analyse evolution of spatial orientation quality in symptomatic and non symptomatic participants.

intervention group: 30 people with a unilateral peripheral vestibular disorder (upvd). process lasting more than three months and symptomatic. aged 18-66 years old. control group: 30 participants without upvd, healthy for the purpose of study. no intervention group: 30 people with a unilateral peripheral vestibular disorder without symptomatology. both groups also aged 18-66. balance quality was registered with static and dynamic posturography. for spatial orientation is was registered visual vertical and visual orientation perception. vestibular disability was also assessed. variables were registered at the beginning and at the end of a vestibular reeducation in upvd participants. vestibular reeducation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. duration of each session: 40 minutes. twice a week. the aim is to compare data before and after intervention with those obtained in compensated patients and control group.

Eligibility criteria:
inclusion criteria: * people diagnosed of upvd * length of process superior to three months * normal vision or corrected by lens or glasses. exclusion criteria: * dizziness or balance alteration due to visual problem or lesion of cns (central nervous system). * balance disturbance due to a locomotor cause * balance perturbation next to resolve. * sharpening or acute phase os symptoms. * difficulties with understanding commands.

Keywords: spatial cognition, vestibular system, motor control
safety and tolerability of vildagliptin versus sitagliptin in patients with type 2 diabetes and severe renal insufficiency (28-week extension study)

Conditions: Diabetes Mellitus, Type 2; Renal Insufficiency

Summary: this clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(t2dm) and severe renal insufficiency (glomerular filtration rate (gfr) \< 30 ml/min) for a period of 52 weeks.


Eligibility criteria:
inclusion criteria: * complete the core study and consent for extension exclusion criteria: * patient unable to comply with core study requirements

Keywords: type 2 diabetes vildagliptin
study on the effectiveness and safety of coil system for intracranial aneurysm embolization

Conditions: Intracranial Aneurysm

Summary: "study on the effectiveness and safety of the coil system for the treatment of intracranial aneurysms embolization" was sponsored by zhuhai tongqiao medical technology co., ltd. the trial design is: prospective, multi-center, randomized, open, parallel positive control, and non-inferiority test. purpose: to compare the data obtained by using the coil system produced by zhuhai tongqiao medical technology co., ltd. and the axium detachable coil produced by medtronic for the embolization of intracranial aneurysms to evaluate the effectiveness and safety of coil system for intracranial aneurysms embolization.

"study on the effectiveness and safety of the coil system for the treatment of intracranial aneurysms embolization" was sponsored by zhuhai tongqiao medical technology co., ltd. the team leader is shanghai changhai hospital and the second affiliated hospital of zhejiang university school of medicine. the trial design is: prospective, multi-center, randomized, open, parallel positive control, and non-inferiority test. purpose: to compare the data obtained by using the coil system produced by zhuhai tongqiao medical technology co., ltd. and the axium detachable coil produced by medtronic for the embolization of intracranial aneurysms to evaluate the effectiveness and safety of coil system for intracranial aneurysms embolization. sample: 228 cases. the subjects will be randomly assigned to the test group or the control group, with 114 cases in each group.

Eligibility criteria:
inclusion criteria: * an intracranial aneurysm was diagnosed by dsa examination of whole cerebral blood vessels, and it is planned to use a coil for the embolization of the target aneurysm * the subject can understand the purpose of the research, show sufficient compliance with the research protocol, and sign an informed consent form exclusion criteria: * multiple aneurysms * blood alveolar aneurysm, fusiform aneurysm, pseudoaneurysm, dissecting aneurysm, infectious aneurysm with arteriovenous malformation * mrs score ≥ 3 * hunt and hess rating≥4 * emergency ruptured aneurysms who need stent * the target aneurysm has previously been treated with vascular embolization or surgery * patients with severe stenosis of the tumor-bearing artery * plt\ 1.5 * having vital organ failure or other serious diseases * received major surgery within 30 days before enrollment, or planned to undergo surgery within 90 days after enrollment * history of allergy or contraindications to antiplatelet drugs, anticoagulant drugs, anesthetics, or contrast agents * patiens with a history of allergies to platinum and tungsten metals * life expectancy \<12 months * pregnant or breastfeeding women * participated in other drug or device clinical trials within 1 month before signing the informed consent * other situations that the researcher judges are not suitable for inclusion

Keywords: intracranial aneurysms embolization